589 related articles for article (PubMed ID: 29544992)
21. Lowering the dietary omega-6: omega-3 does not hinder nonalcoholic fatty-liver disease development in a murine model.
Enos RT; Velázquez KT; McClellan JL; Cranford TL; Walla MD; Murphy EA
Nutr Res; 2015 May; 35(5):449-59. PubMed ID: 25934114
[TBL] [Abstract][Full Text] [Related]
22. An abundant biliary metabolite derived from dietary omega-3 polyunsaturated fatty acids regulates triglycerides.
Grevengoed TJ; Trammell SA; Svenningsen JS; Makarov MV; Nielsen TS; Jacobsen JCB; Treebak JT; Calder PC; Migaud ME; Cravatt BF; Gillum MP
J Clin Invest; 2021 Mar; 131(6):. PubMed ID: 33507883
[TBL] [Abstract][Full Text] [Related]
23. Omega-3 fatty acids and inflammatory processes: from molecules to man.
Calder PC
Biochem Soc Trans; 2017 Oct; 45(5):1105-1115. PubMed ID: 28900017
[TBL] [Abstract][Full Text] [Related]
24. Non-alcoholic fatty liver disease severity and metabolic complications in obese children: impact of omega-3 fatty acids.
Spahis S; Alvarez F; Ahmed N; Dubois J; Jalbout R; Paganelli M; Grzywacz K; Delvin E; Peretti N; Levy E
J Nutr Biochem; 2018 Aug; 58():28-36. PubMed ID: 29864682
[TBL] [Abstract][Full Text] [Related]
25. Long chain omega-3 fatty acids: micronutrients in disguise.
Innis SM; Novak EM; Keller BO
Prostaglandins Leukot Essent Fatty Acids; 2013 Jan; 88(1):91-5. PubMed ID: 22709913
[TBL] [Abstract][Full Text] [Related]
26. Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids.
Davidson MH
Am J Cardiol; 2006 Aug; 98(4A):27i-33i. PubMed ID: 16919514
[TBL] [Abstract][Full Text] [Related]
27. Sake lees extract improves hepatic lipid accumulation in high fat diet-fed mice.
Kubo H; Hoshi M; Matsumoto T; Irie M; Oura S; Tsutsumi H; Hata Y; Yamamoto Y; Saito K
Lipids Health Dis; 2017 Jun; 16(1):106. PubMed ID: 28578672
[TBL] [Abstract][Full Text] [Related]
28. Omacor and omega-3 fatty acids for treatment of coronary artery disease and the pleiotropic effects.
Kar S
Am J Ther; 2014; 21(1):56-66. PubMed ID: 21975796
[TBL] [Abstract][Full Text] [Related]
29. Omega-3 fatty acids and nonalcoholic fatty liver disease in adults and children: where do we stand?
Spooner MH; Jump DB
Curr Opin Clin Nutr Metab Care; 2019 Mar; 22(2):103-110. PubMed ID: 30601174
[TBL] [Abstract][Full Text] [Related]
30. Alpinetin improved high fat diet-induced non-alcoholic fatty liver disease (NAFLD) through improving oxidative stress, inflammatory response and lipid metabolism.
Zhou Y; Ding YL; Zhang JL; Zhang P; Wang JQ; Li ZH
Biomed Pharmacother; 2018 Jan; 97():1397-1408. PubMed ID: 29156529
[TBL] [Abstract][Full Text] [Related]
31. Omega-3 polyunsaturated fatty acid and ursodeoxycholic acid have an additive effect in attenuating diet-induced nonalcoholic steatohepatitis in mice.
Kim JK; Lee KS; Lee DK; Lee SY; Chang HY; Choi J; Lee JI
Exp Mol Med; 2014 Dec; 46(12):e127. PubMed ID: 25523099
[TBL] [Abstract][Full Text] [Related]
32. Omega-3 fatty acids and metabolic partitioning of fatty acids within the liver in the context of nonalcoholic fatty liver disease.
Calder PC
Curr Opin Clin Nutr Metab Care; 2022 Jul; 25(4):248-255. PubMed ID: 35762160
[TBL] [Abstract][Full Text] [Related]
33. Ursodeoxycholyl Lysophosphatidylethanolamide modifies aberrant lipid profiles in NAFLD.
Pathil A; Liebisch G; Okun JG; Chamulitrat W; Schmitz G; Stremmel W
Eur J Clin Invest; 2015 Sep; 45(9):925-31. PubMed ID: 26108973
[TBL] [Abstract][Full Text] [Related]
34. Marine omega-3 fatty acid supplementation in non-alcoholic fatty liver disease: Plasma proteomics in the randomized WELCOME* trial.
Manousopoulou A; Scorletti E; Smith DE; Teng J; Fotopoulos M; Roumeliotis TI; Clough GF; Calder PC; Byrne CD; Garbis SD
Clin Nutr; 2019 Aug; 38(4):1952-1955. PubMed ID: 30172659
[TBL] [Abstract][Full Text] [Related]
35. Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study.
Oscarsson J; Önnerhag K; Risérus U; Sundén M; Johansson L; Jansson PA; Moris L; Nilsson PM; Eriksson JW; Lind L
J Clin Lipidol; 2018; 12(6):1390-1403.e4. PubMed ID: 30197273
[TBL] [Abstract][Full Text] [Related]
36. Systematic review and meta-analysis of controlled intervention studies on the effectiveness of long-chain omega-3 fatty acids in patients with nonalcoholic fatty liver disease.
Musa-Veloso K; Venditti C; Lee HY; Darch M; Floyd S; West S; Simon R
Nutr Rev; 2018 Aug; 76(8):581-602. PubMed ID: 29917092
[TBL] [Abstract][Full Text] [Related]
37. The importance of the long-chain polyunsaturated fatty acid n-6/n-3 ratio in development of non-alcoholic fatty liver associated with obesity.
Valenzuela R; Videla LA
Food Funct; 2011 Nov; 2(11):644-8. PubMed ID: 22008843
[TBL] [Abstract][Full Text] [Related]
38. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia.
McKenney JM; Sica D
Pharmacotherapy; 2007 May; 27(5):715-28. PubMed ID: 17461707
[TBL] [Abstract][Full Text] [Related]
39. Mapping the triglyceride distribution in NAFLD human liver by MALDI imaging mass spectrometry reveals molecular differences in micro and macro steatosis.
Alamri H; Patterson NH; Yang E; Zoroquiain P; Lazaris A; Chaurand P; Metrakos P
Anal Bioanal Chem; 2019 Feb; 411(4):885-894. PubMed ID: 30515538
[TBL] [Abstract][Full Text] [Related]
40. Effect of an 8-month treatment with omega-3 fatty acids (eicosapentaenoic and docosahexaenoic) in patients with cystic fibrosis.
De Vizia B; Raia V; Spano C; Pavlidis C; Coruzzo A; Alessio M
JPEN J Parenter Enteral Nutr; 2003; 27(1):52-7. PubMed ID: 12549599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
